Indian startup CrisprBits raised $3 million in a pre‑Series A round led by Spectrum Impact to expand CRISPR‑based diagnostics, gene‑editing R&D and sustainable biotech initiatives. The company plans to deploy funds to scale assay development, broaden product pipelines and strengthen regulatory and commercialization readiness. The raise highlights continued early‑stage capital flow into CRISPR diagnostics startups focused on low-cost, point-of-need tests. For investors and product teams: CrisprBits’ trajectory will hinge on demonstrating clinical validation, regulatory pathways in target markets and manufacturing scale for reagentized CRISPR assays.